Dissecting the Concept of Superiority in Practice
About this video
Ask a patient with psoriasis if they’ve ever had a swollen joint, and you may hear about a fall on the pickleball court. Ask about their lower back, and you may learn something a screening questionnaire missed. In this Topical Conversation, Ben Lockshin, MD, and Ron Vender, MD, compare how they screen for psoriatic arthritis in a busy dermatology practice. Sometimes the dermatologist is the first to hear about heel pain or a swollen toe. Other times, as Dr Vender notes, the rheumatologist calls for help recognizing subtle skin disease.
When it’s time to choose a biologic, what can a head-to-head trial add? Drs Lockshin and Vender look at BE BOLD, which compared bimekizumab with risankizumab in adults with active psoriatic arthritis. They discuss:
Why most patients receiving bimekizumab were on the PsA dose rather than the psoriasis dose
What an ACR50 response asks of a treatment
Why clear skin and joint improvement belong in the same conversation
They also weigh how soon relief might come, which comorbidities shape the choice of mechanism, and what longer-term follow-up still needs to show.